BACKGROUND: Remission of type 2 diabetes (T2D) is a desired outcome after bariatric surgery (BS). Even if this goal is not achieved, individuals who do not strictly fulfill remission criteria experience an overall improvement. The aim of this study was to evaluate the metabolic control status in patients considered as diabetes "non-remitters." METHODS: A retrospective study of 125 patients (59.2 % women) with preoperative diagnosis of T2D who underwent BS in a single center (2006-2011) was conducted. We collected anthropometric and metabolic parameters before surgery and at 1-year follow-up. T2D remission was defined according to the 2009 consensus statement: glycosylated hemoglobin (HbA1c) <6 %, fasting glucose (FG) <100 mg/dLs, and absence of pharmacologic treatment. We evaluated metabolic status of non-remitters, according to the American Diabetes Association's (ADA) target recommendations: HbA1c <7 %, LDL-c <100 mg/dL, triglycerides <150 mg/dL, and HDL-c >40 (male) or >50 mg/dL (female). STATISTICS: analysis of variance. RESULTS: Baseline characteristics (mean ± SD): age 53.5 ± 9.7 years, BMI 43.5 ± 5.6 kg/m(2), time since diagnosis of T2D 7.7 ± 7.9 years, FG 162.0 ± 56.3 mg/dL, HbA1c 7.7 ± 1.6 %. ADA's target recommendations were present in 12 patients (9.6 %) preoperatively, and in 45 (36.0 %) at 1-year follow-up (p <0.001). Sixty-two (49.6 %) patients did not achieve diabetes remission; 26 (41.9 %) had now diet treatment, 30 (48.4 %) oral medications, and 6 (9.7 %) required insulin. Of the non-remitters, 57 (91.9 %) had HbA1c <7 % and 18 (40.0 %) achieved ADA's target recommendations. There were no differences between remitters and non-remitters in the number of individuals reaching ADA's combined metabolic control. CONCLUSIONS: Although almost 50 % of the patients may not be classified as diabetes remitters, their significant improvement in metabolic control should be regarded as a success, according to most scientific societies' target recommendations.
BACKGROUND: Remission of type 2 diabetes (T2D) is a desired outcome after bariatric surgery (BS). Even if this goal is not achieved, individuals who do not strictly fulfill remission criteria experience an overall improvement. The aim of this study was to evaluate the metabolic control status in patients considered as diabetes "non-remitters." METHODS: A retrospective study of 125 patients (59.2 % women) with preoperative diagnosis of T2D who underwent BS in a single center (2006-2011) was conducted. We collected anthropometric and metabolic parameters before surgery and at 1-year follow-up. T2D remission was defined according to the 2009 consensus statement: glycosylated hemoglobin (HbA1c) <6 %, fasting glucose (FG) <100 mg/dLs, and absence of pharmacologic treatment. We evaluated metabolic status of non-remitters, according to the American Diabetes Association's (ADA) target recommendations: HbA1c <7 %, LDL-c <100 mg/dL, triglycerides <150 mg/dL, and HDL-c >40 (male) or >50 mg/dL (female). STATISTICS: analysis of variance. RESULTS: Baseline characteristics (mean ± SD): age 53.5 ± 9.7 years, BMI 43.5 ± 5.6 kg/m(2), time since diagnosis of T2D 7.7 ± 7.9 years, FG 162.0 ± 56.3 mg/dL, HbA1c 7.7 ± 1.6 %. ADA's target recommendations were present in 12 patients (9.6 %) preoperatively, and in 45 (36.0 %) at 1-year follow-up (p <0.001). Sixty-two (49.6 %) patients did not achieve diabetes remission; 26 (41.9 %) had now diet treatment, 30 (48.4 %) oral medications, and 6 (9.7 %) required insulin. Of the non-remitters, 57 (91.9 %) had HbA1c <7 % and 18 (40.0 %) achieved ADA's target recommendations. There were no differences between remitters and non-remitters in the number of individuals reaching ADA's combined metabolic control. CONCLUSIONS: Although almost 50 % of the patients may not be classified as diabetes remitters, their significant improvement in metabolic control should be regarded as a success, according to most scientific societies' target recommendations.
Authors: Lars Sjöström; Anna-Karin Lindroos; Markku Peltonen; Jarl Torgerson; Claude Bouchard; Björn Carlsson; Sven Dahlgren; Bo Larsson; Kristina Narbro; Carl David Sjöström; Marianne Sullivan; Hans Wedel Journal: N Engl J Med Date: 2004-12-23 Impact factor: 91.245
Authors: John B Buse; Sonia Caprio; William T Cefalu; Antonio Ceriello; Stefano Del Prato; Silvio E Inzucchi; Sue McLaughlin; Gordon L Phillips; R Paul Robertson; Francesco Rubino; Richard Kahn; M Sue Kirkman Journal: Diabetes Care Date: 2009-11 Impact factor: 19.112
Authors: Ana Ramos-Levi; Andres Sanchez-Pernaute; Pilar Matia; Lucio Cabrerizo; Ana Barabash; Carmen Hernandez; Alfonso Calle-Pascual; Antonio Torres; Miguel Rubio Journal: Obes Surg Date: 2013-10 Impact factor: 4.129
Authors: D J Pournaras; E T Aasheim; T T Søvik; R Andrews; D Mahon; R Welbourn; T Olbers; C W le Roux Journal: Br J Surg Date: 2011-10-21 Impact factor: 6.939
Authors: Ana M Ramos-Levi; Lucio Cabrerizo; Pilar Matía; Andrés Sánchez-Pernaute; Antonio J Torres; Miguel A Rubio Journal: BMC Surg Date: 2013-03-28 Impact factor: 2.102
Authors: A Mas-Lorenzo; D Benaiges; J A Flores-Le-Roux; J Pedro-Botet; J M Ramon; A Parri; M Villatoro; J Chillarón; M Pera; L Grande; A Goday Journal: Obes Surg Date: 2014-11 Impact factor: 4.129
Authors: Martín Cuesta; Manuel Fuentes; Miguel Rubio; Elena Bordiu; Ana Barabash; Nuria Garcia de la Torre; Gemma Rojo-Martinez; Sergio Valdes; Federico Soriguer; Joan Josep Vendrell; Ines Maria Urrutia; Emilio Ortega; Eduard Montanya; Eldelmiro Menendez; Ana Lago-Sampedro; Ramón Gomis; Albert Goday; Conxa Castell; Rocio Badia-Guillen; Juan Girbés; Sonia Gaztambide; Josep Franch-Nadal; Elías Delgado Álvarez; Felipe Javier Chaves; Luis Castano; Alfonso L Calle-Pascual Journal: BMJ Open Diabetes Res Care Date: 2020-10